USPTO Patent Grant for Mint Labs Inc. Tractography Image Diagnosis Methods

ChangeBridge: Patent Grants - Diagnosis & Surgery (A61B)

Published March 17th, 2026

Detected March 22nd, 2026

Summary

The USPTO has granted a patent to Mint Labs Inc. for systems and methods to improve tractography images used in diagnosing neurodegenerative diseases. The patent, Reissue USRE050823E1, focuses on enhancing diffusion-based magnetic resonance imaging for damaged nervous systems, potentially serving as a biomarker for patient assessment.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has issued Reissue Patent USRE050823E1 to Mint Labs Inc. This patent covers systems and methods designed to improve tractography images derived from diffusion-based magnetic resonance imaging (dMRI). The innovation aims to overcome limitations of current dMRI parameters in diagnosing neurodegenerative diseases by enhancing images of damaged nervous systems, thereby enabling more accurate tractography. The identified damaged tracks can serve as biomarkers for patient assessment, prognosis, and treatment selection, with potential conversion into clinical scales.

This patent grant is primarily an intellectual property development and does not impose direct regulatory obligations on companies. However, it signifies a technological advancement in the diagnosis and monitoring of neurodegenerative diseases. Companies involved in medical imaging, neurodegenerative disease research, or the development of diagnostic tools may find this patent relevant to their own research and development efforts or potential licensing opportunities. Compliance officers should note this as a development in the technological landscape of diagnostic methods.

Source document (simplified)

← USPTO Patent Grants

Systems and methods for improved tractography images

Reissue USRE050823E1 Kind: E1 Mar 17, 2026

Assignee

Mint Labs Inc.

Inventors

Vesna Prchkovska, Paulo Reis Rodrigues, Marc Ramos Bruach, Pablo Villoslada, Álvaro Abella de Bascarán

Abstract

The present disclosure discusses systems and methods for identifying biomarkers that can help with the diagnosis, prognosis, and treatment choices of patients with neurodegenerative diseases. Diffusion based magnetic resonance imaging can often fail for patients with a neurodegenerative disease because parameters fractional anisotropy, mean diffusivity, and radial diffusivity are based on simple models that can fail in the presence of neurodegeneration, such as demyelination. The present disclosure discusses systems and methods that enhance dMRI images and enable tractography to be performed on images of a damaged nervous system. The damaged tracks identified by the present system can be used as a biomarker for the assessment of patients. In some implementations, the biomarkers are converted into clinical scales that can be used to compare patients to one another or over time.